Skip to main content
Premium Trial:

Request an Annual Quote

Drug & Market Development Productions, Agilent


Drug & Market Development Productions has released a new market report entitled Commercial Opportunities in RNA Interference — The Emerging Revolution.

The report, said D&MD, includes assessments of the projected market impact of RNAi through 2008, the commercial opportunities for using related technologies, those in the industry, the patenting of RNAi, and the technical aspects of the technology.

The chapters of the report can be ordered separately for prices ranging from $250 to $1,000, and the entire report can be purchased for $4,950. Details about the report can be found at http://www.drugand

Agilent said this week that it has introduced the Agilent Total, a new RNA isolation kit it claims is capable of removing 1,000 times more genomic DNA than competing products.

According to Agilent, the kit does not use DNase enzyme, which can compromise the quality of RNA, and it has a pre-filtration column that removes genomic DNA contamination to less than one femtogram per one nanogram of isolated RNA in selected tissues.

Details about the Agilent Total, which is to be made available on Nov. 1, can be found at

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.